Download interactions: TXT MITAB-2.5
| Interaction | Interactor | Experiments | Homologs | Category | Interaction Score |
Confidence |
|---|---|---|---|---|---|---|
|
CAV1
Caveolin-1 |
3 |
4 |
High-throughput |
0.667 | High |
|
|
TRPM4
Transient receptor potential cation channel subfamily M member 4 |
3 |
2 |
High-throughput |
0.667 | High |
|
|
SL9A6
Sodium/hydrogen exchanger 6 |
3 |
2 |
High-throughput |
0.667 | High |
|
|
NU5M
NADH-ubiquinone oxidoreductase chain 5 |
3 |
4 |
High-throughput |
0.609 | High |
|
|
GLT11
Polypeptide N-acetylgalactosaminyltransferase 11 |
3 |
3 |
High-throughput |
0.609 | High |
|
|
PP1RA
Serine/threonine-protein phosphatase 1 regulatory subunit 10 |
3 |
6 |
High-throughput |
0.609 | High |
|
|
GHITM
Growth hormone-inducible transmembrane protein |
3 |
2 |
High-throughput |
0.609 | High |
|
|
NDUB3
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3 |
2 |
1 |
High-throughput |
0.558 | High |
|
|
SAFB2
Scaffold attachment factor B2 |
2 |
13 |
High-throughput |
0.558 | High |
|
|
MPRIP
Myosin phosphatase Rho-interacting protein |
2 |
13 |
High-throughput |
0.558 | High |
|
|
NU2M
NADH-ubiquinone oxidoreductase chain 2 |
1 |
4 |
High-throughput |
0.489 | High |
|
|
REEP3
Receptor expression-enhancing protein 3 |
1 |
3 |
High-throughput |
0.489 | High |
|
|
PLCC
1-acyl-sn-glycerol-3-phosphate acyltransferase gamma |
1 |
3 |
High-throughput |
0.479 | High |
|
|
LIMA1
LIM domain and actin-binding protein 1 |
1 |
6 |
High-throughput |
0.479 | High |
|
|
AG10A
Dol-P-Glc:Glc(2)Man(9)GlcNAc(2)-PP-Dol alpha-1,2-glucosyltransferase |
1 |
0 |
High-throughput |
0.458 | High |
|
|
PIGU
Phosphatidylinositol glycan anchor biosynthesis class U protein |
1 |
0 |
High-throughput |
0.458 | High |
|
|
INT7
Integrator complex subunit 7 |
3 |
0 |
High-throughput |
0.347 | High |
|
|
RPB7
DNA-directed RNA polymerase II subunit RPB7 |
1 |
0 |
High-throughput |
0.282 | High |
|
|
GPHRB
Golgi pH regulator B |
1 |
0 |
High-throughput |
0.249 | Low |
Service provided by Combinatics, Japan
Last updated: 15 Jul 2024
